In a positive development for India's fight against the Covid-19 pandemic, millions of doses of the Covishield vaccine, which is being manufactured by the Pune based Serum Institute of India (SII), have passed the quality test at the government's laboratory for testing vaccines, reports Economic Times.
As many as 25 million doses of the Covishield vaccine are said to have been tested for quality at the Kasauli based Central Drug Laboratory (CDL). Now, these doses can be rolled out for administration as soon as Covishield is approved and cleared by the Drugs Controller General of India (DCGI).
Covishield vaccine has been developed by the University of Oxford in association with pharmaceutical major AstraZeneca. The said vaccine is currently undergoing Phase-III clinical trials in India and SII has already applied for an emergency use authorisation (EUA) of the same.
Led by Adar Poonawalla, SII, which is the world's largest vaccine manufacturer in term of doses, has already begun stockpiling doses of Covishield which can be rolled out once it is approved for administration in the nation. Recently, Prime Minister (PM) Narendra Modi had also visited the company's campus in Pune to review the progress of vaccine development.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 999/year is the best way you can support our efforts.